Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Hermanson, Spencer B ^a   Carlson, Coby B ^a   Riddle, Steven M ^a   Zhao, Jing ^b   Vogel, Kurt W ^a   Nichols, R Jeremy ^b   Bi, Kun ^a  

^a Life Technologies Corporation   (United States)

^b PARKINSON S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; AMINOPURVALANOL A; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BAY 117821; CHECKPOINT KINASE 1; GREEN FLUORESCENT PROTEIN; GW 441756; H 1152; I KAPPA B; INDIRUBIN 3 OXIME; INTERLEUKIN 2 RECEPTOR ALPHA; LEUCINE RICH REPEAT KINASE 2; LEUCINE RICH REPEAT KINASE 2 INHIBITOR; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NSC 663284; NSC 95397; PD 407824; PROTEIN KINASE INHIBITOR; RO 1069920; SB 218078; SERINE; SUNITINIB; TAE 684; TERBIUM; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE LIBRARY; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOPRECIPITATION; INHIBITORY CONCENTRATION 50; MODELS, GENETIC; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SERINE;

EID: 84865515027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043580     Document Type: Article

References (38)

1. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7: 583-590.
2. Cookson MR, (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11: 791-797.
3. Covy JP, Giasson BI, (2009) Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun 378: 473-477.
4. Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16: 998-1000.
5. Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, et al. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 424: 47-60.
6. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, et al. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313: 3658-3670.
7. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, et al. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357: 668-671.
8. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102: 16842-16847.
9. West AB, Moore DJ, Choi C, Andrabi SA, Li X, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223-232.
10. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, et al. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9: 1231-1233.
11. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23: 329-341.
12. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105: 1048-1056.
13. Ramsden N, Perrin J, Ren Z, Lee BD, Zinn N, et al. (2011) Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson's Disease-Related Toxicity in Human Neurons. ACS Chem Biol 6: 1021-1028.
14. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 7: 203-205.
15. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS, (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett 22: 1864-1869.
16. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, et al. (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430: 405-413.
17. Greggio E, Taymans JM, Zhen EY, Ryder J, Vancraenenbroeck R, et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 389: 449-454.
18. Kamikawaji S, Ito G, Iwatsubo T, (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry 48: 10963-10975.
19. Webber PJ, Smith AD, Sen S, Renfrow MB, Mobley JA, et al. (2011) Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol 412: 94-110.
20. Li X, Wang QJ, Pan N, Lee S, Zhao Y, et al. (2011) Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 6: e17153.
21. Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, et al. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 430: 393-404.
22. Doggett EA, Zhao J, Mork CN, Hu D, Nichols RJ, (2012) Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. J Neurochem 120: 37-45.
23. Reichling LJ, Riddle SM, (2009) Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochem Biophys Res Commun 384: 255-258.
24. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317.
25. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
26. Lebakken CS, Riddle SM, Singh U, Frazee WJ, Eliason HC, et al. (2009) Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. J Biomol Screen 14: 924-935.
27. Robers MB, Horton RA, Bercher MR, Vogel KW, Machleidt T, (2008) High-throughput cellular assays for regulated posttranslational modifications. Anal Biochem 372: 189-197.
28. Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, et al. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18: 4022-4034.
29. Kett LR, Boassa D, Ho CC, Rideout HJ, Hu J, et al. (2012) LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet 21: 890-899.
30. Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, et al. (2008) Investigation of leucine-rich repeat kinase 2 Enzymological properties and novel assays. FEBS J 276: 466-478.
31. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
32. Wood ER, Kuyper L, Petrov KG, Hunter RN 3rd, Harris PA, et al (2004) Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett 14: 953-957.
33. Swinney DC, Xu YZ, Scarafia LE, Lee I, Mak AY, et al. (2002) A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats. J Biol Chem 277: 23573-23581.
34. Han Y, Shen H, Carr BI, Wipf P, Lazo JS, et al. (2004) NAD(P)H:quinone oxidoreductase-1-dependent and-independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors. J Pharmacol Exp Ther 309: 64-70.
35. Leung-Pineda V, Ryan CE, Piwnica-Worms H, (2006) Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 26: 7529-7538.
36. Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, et al. (2009) Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 7: 43.
37. Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, et al. (2011) Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A 108: 1439-1444.
38. Saunders-Pullman R, Barrett MJ, Stanley KM, Luciano MS, Shanker V, et al. (2010) LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord 25: 2536-2541.